Investor Login

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd) negative brain lesions. European Commission approval is expected by the end of September 2026.

0-Homepage Feature / 0-Megaphone / Minoryx - 07/26/2026

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

BOSTON, June 01, 2026 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.

Aura - 06/02/2026

Horizon Quantum and IonQ Enter into Strategic Agreement to Unlock Quantum Potential

SINGAPORE, COLLEGE PARK, Md., April 9, 2026 — Horizon Quantum Holdings Ltd. (“Horizon Quantum”), a pioneer of software infrastructure for quantum applications and IonQ — the world’s leading quantum platform company — today announced a strategic agreement. Horizon Quantum will purchase one of IonQ’s first 6th-generation, chip-based 256-qubit trapped-ion systems, in furtherance of Horizon Quantum’s mission to unlock the full potential of quantum computing with its software platform. The acquisition of the 256-qubit system marks a further step in Horizon Quantum’s efforts to enable broad quantum advantage.

Horizon - 04/09/2026

Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG

SAN CARLOS, Calif.--April 2, 2026--Glycomine, Inc. announced today that enrollment has been completed in the Phase 2b POLAR study, a global, randomized, double-blind, placebo-controlled clinical trial evaluating GLM101 for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). PMM2-CDG is a rare genetic disorder that causes serious neurological and multisystem impairments. More than 90% of patients with PMM2-CDG have ataxia, a key neurological manifestation and driver of disease burden. There are currently no approved treatments for PMM2-CDG.

Glycomine - 04/02/2026

Horizon Quantum, a Leading Quantum Software Infrastructure Company, Closes its Business Combination with dMY Squared

SINGAPORE AND LAS VEGAS, NV, March 19, 2026 — Horizon Quantum Computing Pte. Ltd. (“Horizon Quantum”), a pioneer of software infrastructure for quantum applications, today announced that it has completed its previously announced business combination (the “Business Combination”) with dMY Squared Technology Group, Inc. (“dMY”) (OTC: “DMYY”, “DMYYU” and “DMYYW”), a publicly traded special purpose acquisition company. The Business Combination was approved by dMY’s shareholders at dMY’s special meeting held on March 17, 2026. On March 20, 2026, the combined company’s Class A ordinary shares and warrants will begin trading on Nasdaq under the ticker symbols “HQ” and “HQWWW,” respectively.

Horizon - 03/19/2026

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal’s pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opportunity in the $40 billion global anticoagulation market.

Veralox Therapeutics - 12/11/2025

Horizon Quantum Computing Pte. Ltd. and dMY Squared Technology Group, Inc. Announce $110 Million PIPE Investment to Support Proposed Business Combination

SINGAPORE & LAS VEGAS--Dec. 5, 2025--Horizon Quantum Computing Pte. Ltd. (“Horizon Quantum”), a pioneer of software infrastructure for quantum applications, and dMY Squared Technology Group, Inc. (“dMY Squared”) (OTCQB: “DMYY”), a publicly traded special purpose acquisition company, announced that they have entered into subscription agreements with investors for a $110 million PIPE financing comprised of common equity, priced at the SPAC redemption price per share, to support the previously announced proposed business combination (the “Business Combination”) which is expected to close in the first quarter of 2026.

Horizon - 12/05/2025

Horizon Quantum Becomes First Quantum Software Company to Own and Operate Quantum Computer

SINGAPORE--Dec. 3, 2025--Horizon Quantum Computing Pte. Ltd., a pioneer of software infrastructure for quantum applications, today announced that it has completed the assembly and integration of a first quantum computer at its Singapore headquarters. The system is now fully operational. Assembled from components and operated directly by Horizon Quantum’s team, this system makes Horizon Quantum the first quantum software company to own and run a quantum computer.

Horizon - 12/05/2025

CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056)

SAN CARLOS, Calif.--Nov 10, 2025--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from a Phase 1 study with CuraAX (CST-3056). Data were presented by Gabriel Vargas, MD, PhD, chief medical officer, CuraSen Therapeutics, in both an oral and poster presentation at the 36th International Symposium on the Autonomic Nervous System, held November 5-8 in Clearwater Beach, FL.

CuraSen Therapeutcis - 11/11/2025
logo_white
veteran_logo_white
NVCA
bio
nc-biotech